摘要
目的研究宫腔灌注人自体PBMC对反复种植失败患者妊娠结局的影响。方法选取2019年6月至2021年12月我院行解冻移植的反复种植失败患者80例,以简单随机法分为试验组和对照组各40例,试验组在解冻移植前1天,3天分别宫腔灌注自体PBMC,对照组则于同一时间宫腔灌注同等量的生理盐水,比较两组患者的一般情况、妊娠结局等。结果对两组患者的一般情况包括年龄、不孕类型、不孕的年限、体重指数进行比较,差异均无统计学意义(P>0.05),两组患者FET周期的子宫内膜厚度、A型子宫内膜比率、移植胚胎个数、流产率及异位妊娠率比较,差异无统计学意义(P>0.05),试验组的胚胎种植率以及临床妊娠率显著高于对照组,差异有统计学意义(P<0.05)。结论RIF患者在再次胚胎移植前宫腔灌注人自体PBMC可显著提高胚胎的种植率及临床妊娠率,同时不增加流产率及异位妊娠率。
Objective To study the effect of intrauterine infusion of human autologous PBMC on pregnancy outcome in patientswith recurrent implant failure.Methods A total of 80 patients with recurrent implantation failure who underwent thawing transplantation in our hospital from June 2019 to December 2021 were selected and randomly divided into the experimental group and the control group,with 40 cases in each group.The experimental group received intrauterine perfusion of autologous PBMC 1 day and 3 days before thawing transplantation,while the treated group received intrauterine perfusion of the same amount of normal saline at the same time.The general conditions and pregnancy outcome of the patients in two groups were compared.Results There was no statistically significant difference in the general situations of the two groups,including age,infertility type,duration of infertility and BMI(P>0.05).There was no significant difference in endometrial thickness,type A endometrial ratio,number of transplanted embryos,abortion rate and ectopic pregnancy rate in the FET cycle(P>0.05),while the embryo implantation rate and clinical pregnancy rate in the experimental group were significantly higher than those in the control group(P<0.05).Conclusion Intrauterine infusion of autologous PBMC in RIF patients before reimplantation can significantly increase implantation rate and clinical pregnancy rate,without increasing abortion rate and ectopic pregnancy rate.
作者
李洁
杨丽娟
刘居理
黄玉芳
胥杜娟
胡硕楠
薛洁
LI Jie;YANG Lijuan;LIU Juli;HUANG Yufang;XU Dujuan;HU Shuonan;XUE Jie(Nanchang Reproductive Hospital,Nanchang 330001 China)
出处
《现代诊断与治疗》
CAS
2022年第5期636-638,共3页
Modern Diagnosis and Treatment
基金
江西省卫生健康委科技计划(项目编号20204106)。